Home/Pipeline/MRDVision

MRDVision

Minimal Residual Disease (MRD) Monitoring

CommercialActive

Key Facts

Indication
Minimal Residual Disease (MRD) Monitoring
Phase
Commercial
Status
Active
Company

About Inocras

Inocras is a commercial-stage diagnostics and services company leveraging whole genome sequencing (WGS) and advanced bioinformatics to provide actionable insights in oncology and rare disease. Its core offerings include CancerVision for solid tumors, MRDVision for minimal residual disease detection, and RareVision for rare genetic disorders, all delivered through a CAP/CLIA lab with a two-week turnaround. The company serves patients, healthcare providers, and researchers, positioning itself at the intersection of clinical diagnostics and genomic research services.

View full company profile

Therapeutic Areas